The Hidden Challenge in Autoimmune Thyroid Testing: Choosing the Right Anti-TPO Materials for Quality Control Manufacturing

Autoimmune thyroid diseases affect millions of people worldwide and are among the most frequently diagnosed autoimmune disorders. As the demand for accurate thyroid diagnostics continues to grow, so too does the need for high-quality quality control (QC) and calibrator materials that ensure reliable test performance. While much attention is given to developing sensitive and specific anti-thyroid peroxidase (anti-TPO) assays, an equally important challenge is the sourcing of biological materials that enable the manufacture of consistent, clinically relevant quality control materials.

For manufacturers of QC materials and calibrators, selecting the right anti-TPO material is also critical to achieving reliable lot-to-lot performance, maintaining long-term supply and supporting confidence in diagnostic testing.

Why Anti-TPO Testing Matters

Anti-thyroid peroxidase (anti-TPO) antibodies are recognised as one of the most important biomarkers for autoimmune thyroid disease. They are routinely measured to aid the diagnosis and monitoring of conditions including:

• Hashimoto’s thyroiditis
• Graves’ disease
• Postpartum thyroiditis

In many patients, anti-TPO antibodies are present long before clinical symptoms appear, making them an important marker for early disease detection and ongoing patient management.

Increasing Anti-TPO testing demand

The demand for anti-TPO tests is steadily increasing. This growth is driven by the rising prevalence of autoimmune thyroid diseases and an overall shift toward preventive healthcare.

• Rising Autoimmune Cases

The global anti-TPO testing market is growing at a compound annual growth rate of roughly 7.2%, with an aging population disproportionately affected by thyroid dysfunctions.¹

• Routine Screening

Widespread routine screening and initiatives to catch thyroid issues early are significantly boosting testing volumes.²

• Pregnancy Monitoring

US guidelines recommend checking anti-TPO levels in pregnant women to assess the risk of postpartum thyroiditis and miscarriage. ³

The Challenge Doesn’t End When the Assay Is Commercialised

Once an anti-TPO assay has been validated and commercialised, manufacturers of quality control materials face a different challenge, to manufacture quality controls that perform consistently over many production lots while behaving as closely as possible to authentic patient samples.

Achieving this requires biological materials that offer both clinical relevance and dependable supply, something that is becoming increasingly difficult as demand for autoimmune thyroid testing continues to grow.

Why Native Anti-TPO Materials Are Difficult to Source

Although autoimmune thyroid disease is common, sourcing suitable anti-TPO-positive biospecimens for quality control manufacturing presents several challenges.

• High-Titre Donors Are Limited

Only a proportion of patients produce antibody levels suitable for QC manufacturing. Improved patient management guidelines and targeted therapies mean conditions like Hashimoto’s thyroiditis are being caught and managed much earlier. Early treatment and supplementation protocols (such as selenium and vitamin D) can successfully suppress and lower these antibody levels over time. As a result, fewer patients maintain the exceptionally high, raw, untreated titres that were historically more common. ⁴ As a result, finding donors with sufficiently high anti-TPO concentrations can be a challenge.

• Natural Biological Variation

Every patient sample is different. Anti-TPO antibody concentrations and biological characteristics vary naturally, making it challenging to achieve consistent manufacturing lots using donor-derived material.

• Supply

Native disease-state biospecimens rely entirely on donor availability. Securing sufficient volumes of well-characterised material to support long-term commercial manufacturing programmes requires extensive collection networks and careful planning.

Native Biospecimens Remain the Gold Standard

Despite these challenges, native anti-TPO-positive serum and plasma remain the benchmark for clinically relevant quality control materials.

Because they contain naturally occurring human antibodies within their original biological matrix, native biospecimens closely resemble the samples analysed in clinical laboratories every day. This helps manufacturers produce quality controls that reflect real-world assay performance, perform reliably across a range of diagnostic platforms and maintain confidence in patient testing.

For this reason, native anti-TPO biospecimens continue to play an essential role in establishing clinically representative quality control materials.

Human Fc TPO Antibodies: Supporting Long-Term Manufacturing

Engineered Human Fc anti-TPO antibodies provide an alternative solution by offering reproducible antibody performance with a sustainable manufacturing supply.

Whilst some recombinant antibodies lack key post-translational modifications or fail to achieve the complex folding of native immunoglobulins, engineered Human Fc antibodies achieve both enabling performance that closely reflects native disease-state material. While conventional single monoclonal antibodies may not fully reproduce the heterogeneous characteristics of native polyclonal patient samples, carefully selected Human Fc antibodies can demonstrate highly native-like analytical performance, including excellent assay reactivity and linearity where validated.

For quality control manufacturers, Human Fc antibodies can provide:

• Excellent lot-to-lot consistency
• Reliable long-term supply
• Reduced dependence on scarce donor material
• Greater manufacturing scalability
• Improved production planning and supply continuity

Native Biospecimens vs Human Fc Antibodies

Conclusion

The demand for autoimmune thyroid testing continues to increase, placing greater emphasis on the quality, consistency and sustainability of the biological materials used in quality control manufacturing.

Logical Biological offers reliable access to native anti-TPO-positive serum and plasma, and engineered Human Fc anti-TPO IgG antibodies, giving QC manufacturers greater flexibility to select the material best suited to their performance, consistency and supply requirements.

References:

1. Data Insights Report: Anti Thyroid Peroxidase Antibody Testing Market. datainsightsreports.com/reports/anti-thyroid-peroxidase-antibody-testing-market-202227
2. Fortune Business Insights Report: Thyroid Function Test Market Size, Share and Analysis by Type. fortunebusinessinsights.com/industry-reports/thyroid-function-test-market-101037
3. Mayo Clinic Overview: Thyroid peroxidase antibody test: What is it? mayoclinic.org/diseases-conditions/hashimotos-disease/expert-answers/thyroid-disease/faq-20058114
4. T Siriwardhane et al. Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease. Autoimmune Dis. Jul 28;2019:1684074. doi.org/10.1155/2019/1684074